Skip to content
Screener

Whitehawk Therapeutics WHWK Q2 2025 earnings

Reported August 7, 2025 · Before market open

Revenue-
EPS-$0.76Miss by $1.25
EPS estimate$0.49

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.27

Financials

Q2 2025

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$54.7M-251%
Net income-$52.6M-261%
EPS (diluted)-$0.76-40.7%

Balance sheet

See full
Cash & equivalents$144.9M+252%
Total equity$172.1M+118%
Total assets$180.8M+77.9%

Cash flow

See full
Operating cash flow-$53.0M-478%
CapEx$1.0K-99.8%
Free cash flow-$53.0M-446%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$89.04M—
P/S4.1×—

Profitability

See full
Gross margin89.1%+1.9pp
Operating margin-473.8%+702pp
Net margin-48.2%-21.8pp
FCF margin-446.8%+29,944pp

Returns & leverage

See full
Return on equity-8.3%-3.9pp
Current ratio20.4×+16.2×

Segments

By segment

See full
Reportable--100%

FAQ

When did Whitehawk Therapeutics report Q2 2025 earnings?
Whitehawk Therapeutics (WHWK) reported Q2 2025 earnings on August 7, 2025 before market open.
What were Whitehawk Therapeutics's Q2 2025 revenue and EPS?
Whitehawk Therapeutics reported revenue of - and eps of $-0.76 for Q2 2025.
Did Whitehawk Therapeutics beat estimates in Q2 2025?
EPS missed the consensus estimate of $0.49 by $1.25.
Where can I find Whitehawk Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-104592) and the 10-Q periodic report (0000950170-25-105081) directly on SEC EDGAR. The filing index links above go to sec.gov.